138 related articles for article (PubMed ID: 9132558)
1. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Canpolat C; Pearson P; Robertson R; Jaffe N
Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
6. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
7. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
9. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Berrak SG; Pearson M; Berberoğlu S; Ilhan IE; Jaffe N
Pediatr Blood Cancer; 2005 Mar; 44(3):215-9. PubMed ID: 15503294
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
12. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
13. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
14. [Ifosfamide-induced nephrotoxicity].
Rossi R; Rath B; Ullrich K; Ehrich JH
Monatsschr Kinderheilkd; 1993 Jul; 141(7):594-601. PubMed ID: 8413339
[TBL] [Abstract][Full Text] [Related]
15. Mesna excretion and ifosfamide nephrotoxicity in children.
Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Skinner R; Cotterill SJ; Stevens MC
Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
[TBL] [Abstract][Full Text] [Related]
17. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
Ferrari S; del Prever AB; Palmerini E; Staals E; Berta M; Balladelli A; Picci P; Fagioli F; Bacci G; Vanel D
Pediatr Blood Cancer; 2009 May; 52(5):581-4. PubMed ID: 19142994
[TBL] [Abstract][Full Text] [Related]
18. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
19. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
[TBL] [Abstract][Full Text] [Related]
20. [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Umeda T; Kitoh M; Tatezaki S; Satoh T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):509-14. PubMed ID: 8452388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
